Jeffrey A Meyerhardt
Overview
Explore the profile of Jeffrey A Meyerhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
405
Citations
18091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown J, Ma C, Shi Q, Saltz L, Shields A, Meyerhardt J
Cancer
. 2025 Feb;
131(5):e35727.
PMID: 39989023
Background: Colon cancer patients have inferior overall survival than a matched general population (MGP). It is unknown if physical activity is associated with a reduction in this survival disparity. Methods:...
2.
Lau M, Borowsky J, Vayrynen J, Haruki K, Zhao M, Dias Costa A, et al.
PLoS Comput Biol
. 2025 Feb;
21(2):e1012707.
PMID: 39965007
Background: Growing evidence supports the importance of characterizing the organizational patterns of various cellular constituents in the tumor microenvironment in precision oncology. Most existing data on immune cell infiltrates in...
3.
Blackstone E, Efficace F, Meyerhardt J, Abel G
J Clin Oncol
. 2025 Jan;
JCO2402021.
PMID: 39836934
No abstract available.
4.
Downie J, Joshi A, Geraghty C, Guercio B, Zeleznik O, Song M, et al.
J Natl Cancer Inst
. 2024 Oct;
117(3):517-528.
PMID: 39468739
Background: Metabolomic profiles may influence colorectal cancer (CRC) development. Few studies have performed prediagnostic metabolome-wide analyses with CRC risk. Methods: We conducted a nested case-control study among women (Nurses' Health...
5.
Park R, Parikh M, Pappas L, Sade-Feldman M, Kulkarni A, Bi L, et al.
medRxiv
. 2024 Oct;
PMID: 39417106
Biliary tract cancers demonstrate profound therapeutic resistance, and broadly effective therapies for refractory disease are lacking. We conducted a single-arm, second-line phase II trial combining DKN-01, a humanized monoclonal antibody...
6.
Compton S, Yang S, Madere J, Weltzien E, Caan B, Meyerhardt J, et al.
Cancer
. 2024 Oct;
131(1):e35599.
PMID: 39369275
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting chemotoxicity caused by oxaliplatin. This study investigated the relationship between dietary quality and the development of moderate and/or severe CIPN...
7.
Chan J, Geyer S, Zemla T, Knopp M, Behr S, Pulsipher S, et al.
N Engl J Med
. 2024 Sep;
392(7):653-665.
PMID: 39282913
Background: Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear. Methods:...
8.
Cheng E, Ou F, Gatten C, Ma C, Venook A, Lenz H, et al.
J Natl Cancer Inst
. 2024 Aug;
117(1):169-179.
PMID: 39212617
Background: A plant-based diet is associated with better survival among patients with nonmetastatic colorectal cancer (CRC), but its association in metastatic CRC is unknown. Methods: Using an National Cancer Institute-sponsored...
9.
Brown J, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, et al.
J Natl Cancer Inst
. 2024 Aug;
116(12):2032-2039.
PMID: 39180477
Background: Inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset...
10.
Singh H, Lowder K, Kapner K, Kelly R, Zheng H, McCleary N, et al.
Nat Commun
. 2024 Aug;
15(1):6833.
PMID: 39122726
Preclinical studies suggest that simultaneous HER2/VEGF blockade may have cooperative effects in gastroesophageal adenocarcinomas. In a single-arm investigator initiated clinical trial for patients with untreated advanced HER2+ gastroesophageal adenocarcinoma, bevacizumab...